Key result
Patients with congenital heart disease and pulmonary hypertension had higher plasma ADMA levels (median 0.55 microM/l) than those without pulmonary hypertension (0.30 microM/l) or controls (p<0.01).
Why the study?
Are plasma levels of ADMA increased in patients with congenital heart disease and pulmonary hypertension?
Population
28 children and young adults, including 20 with congenital heart disease undergoing cardiac catheterization…
Design
Cross-sectional
Authors
Loading...
May indicate endothelial dysfunction in congenital heart disease with pulmonary hypertension; leaves open biomarker role pending larger studies.
Observational (n=28)
Are plasma levels of ADMA increased in patients with congenital heart disease and pulmonary hypertension?
Absolute Event Rate: 0.55% vs 0.3%
p-value: p=< 0.01
Increased levels of ADMA in patients with congenital heart disease and pulmonary hypertension suggest that inhibition of nitric oxide synthase may contribute to the pathophysiology of pulmonary hypertension in this population.
Gorenflo et al. (2001) conducted an observational in Congenital heart disease and pulmonary hypertension (n=28). Pulmonary hypertension vs. Congenital heart disease without pulmonary hypertension and controls was evaluated on Plasma levels of Asymmetrical dimethyl-L-arginine (ADMA) (p=< 0.01). Patients with congenital heart disease and pulmonary hypertension had higher plasma ADMA levels (median 0.55 microM/l) than those without pulmonary hypertension (0.30 microM/l) or controls (p<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: